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Association of circulating 25-hydroxyvitamin D levels with 
hypertension and blood pressure values in Korean adults: 
A Mendelian randomization study on a subset of the Korea National 
Health and Nutrition Survey 2011-2012 population
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1Department of Public Health Sciences, BK21PLUS Program in Embodiment: Health-Society Interaction, Graduate School, Korea University, Seoul 02841, Republic 
of Korea
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BACKGROUND/OBJECTIVES: Lower circulating 25-hydroxyvitamin D [25(OH)D] levels are associated with a higher risk of hypertension 
(HTN); however, it remains unclear whether the relationship is causal. We aimed to evaluate the causal effects of circulating 
25(OH)D levels on the prevalence of HTN in the Korean population using the Mendelian randomization (MR) approach. 
SUBJECTS/METHODS: Epidemiological data, serum 25(OH)D data, and genomic DNA biospecimens were obtained from 2,591 
participants, a subset of the study population in the Korea National Health and Nutrition Survey 2011-2012. Five 25(OH)D-related 
single nucleotide polymorphisms (SNPs; DHCR7 rs12785878, CYP2R1 rs10741657, CYP2R1 rs12794714, CYP24A1 rs6013897, and 
GC rs2282679), identified a priori from genome-wide association studies, were used as instrument variables (IVs) for serum 
25(OH)D levels. In the MR analysis, we performed IV analyses using the two-stage least squares method. 
RESULTS: In the observational analysis, circulating 25(OH)D levels were found to be inversely associated with the HTN prevalence 
in ordinary least squares models (odds ratio: 0.97, 95% confidence interval: 0.96, 0.99) after adjusting for the potential confounders. 
There were differences in the circulating 25(OH)D levels across genotypes of individual SNPs. In the MR analysis, using individual 
SNPs as IVs, 25(OH)D levels were not associated with the HTN prevalence. 
CONCLUSIONS: We found no association between genetically determined circulating 25(OH)D levels and HTN in Korean adults. 
Our results are listed owing to the relatively small sample size and possible weak instrument bias; therefore, further studies 
are needed to confirm these results.
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INTRODUCTION5)
There have been inconsistent reports on the association 
between serum vitamin D levels and the risk of hypertension 
(HTN). Meta-analyses of prospective studies [1,2] and cross- 
sectional studies [1] have shown that low vitamin D levels are 
associated with an increased risk of HTN. In contrast, a 
meta-analysis of 30 randomized controlled trials failed to show 
evidence of an association, suggesting that vitamin D supple-
mentation may not result in an overall reduction in the blood 
pressure (BP) value [3]. Therefore, it remains unclear whether 
the role of vitamin D in BP and HTN is causal.
Estimates derived from observational studies may be biased 
because of confounders (environmental and behavioral), 
systematic error, and/or reverse causation [1,2]. For example, 
the association between serum 25-hydroxyvitamin D [25(OH)D] 
levels and HTN could be explained by other factors (e.g., 
obesity) that affect serum 25(OH)D levels and HTN risk [1,4,5]. 
These factors may confound the association between serum 
25(OH)D levels and HTN, giving biased results. Even after 
appropriate adjustments, we were unable to eliminate the effect 
of all the potential confounders. Moreover, several studies have 
suggested that low serum 25(OH)D levels result from disease 
progression, indicating the possibility of reverse causality [6]. 
Low serum 25(OH)D levels can be influenced by HTN onset, 
indicating the possibility of reverse causation [6,7]. Furthermore, 
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Fig. 1. Flow chart of the study participant selection
several studies have suggested that serum 25(OH)D levels are 
a marker, rather than a cause, of disease outcome [8,9].
The mendelian randomization (MR) approach was proposed 
to strengthen the causal inferences using genetic variants 
associated with an exposure phenotype as instrumental 
variables (IVs) [10-12]. This approach is based on Mendel’s laws 
of segregation and independent assortment; this law states that 
genetic variants are randomly allocated during meiosis and 
these genetic variants are unlikely to be influenced by factors 
that bias observational studies. Therefore, the effect estimates 
from MR analyses are unlikely to be confounded. Reverse 
causation is also unlikely, because the outcome (i.e., HTN) does 
not determine which 25(OH)D-associated single nucleotide 
polymorphisms (SNPs) is inherited.
A recent large European MR study concluded that higher 
serum 25(OH)D levels predicted using a 25(OH)D synthesis score 
(DHCR7 rs12785878 and CYP2R1 rs12794714,) are associated 
with lower BP value and a lower risk of HTN [13]. In another 
study on a European population, a similar pattern of association 
was found with genetic variants in regions related to 25(OH)D 
metabolism (CYP24A1) [14]. However, the role of vitamin D in 
cardiovascular health, including BP and HTN, in Korean popula-
tion is unclear because most studies have focused on European 
population. Further, to our knowledge, no study has investigated 
the relationship between serum vitamin D levels and BP using 
the MR approach in the Korean population.
Here, we investigated the association of serum vitamin D 
levels with the HTN risk in 2,591 Korean subjects using the MR 
approach. We used five SNPs (DHCR7 rs12785878 Chr.11: 
71456403; CYP2R1 rs10741657 Chr.11:14893332; CYP2R1 rs1279 
4714 Chr.11:14892029; CYP24A1 rs6013897 Chr.20:54125940; 
and GC rs2282679 Chr.4:71742666,) that were identified a priori 
from previous genome-wide association studies (GWASs) [15, 
16] and MR studies of vitamin D [17-20], as IVs for 25(OH)D 
levels because they had the potential to satisfy the assumptions 
of MR and these variants reportedly account for a large 
proportion of the difference in serum 25(OH)D levels [15,21,22]. 
These SNPs are related to the genes known to affect synthesis 
(DHCR7: endogenous production; CYP2R1: liver conversion) and 
metabolism (CYP24A1: degradation of vitamin D, GC: transpor-
tation of vitamin D to target cells) of 25(OH)D. Previous MR 
studies have used these SNPs as IVs to verify the causal effects 
of vitamin D on the risk of multiple diseases including type 
2 diabetes [17], multiple sclerosis [18], and ovarian cancer [19] 
in European and Chinese populations.
SUBJECTS AND METHODS
Study participants
We used data from the Korea National Health and Nutrition 
Examination Survey (KNHANES) 2011-2012, a nationally repre-
sentative cross-sectional survey conducted by the Korea Centers 
for Disease Control and Prevention. A stratified multistage 
probability sampling design was used to obtain a nationally 
representative sample of Korean subjects based on the 
geographical area, sex, and age from a household registry. The 
KNHANES comprises the following three different sections: 
health examination, health interview, and nutrition survey. 
Detailed information on the KNHANES is available elsewhere 
[23]. Among the 16,576 participants (8,518 participants in 2011 
and 8,058 participants in 2012), those aged < 20 years were 
excluded. We also excluded participants who had been diagnosed 
with cancer and women who were pregnant or lactating. After 
further excluding participants with missing or insufficient DNA 
samples (n = 9,445), 2,600 eligible participants were available for 
genotyping. Of these, nine with had missing values in their 
genotype data or BP measurements were excluded. Finally, 
2,591 participants (490 participants in 2011 and 2,101 partici-
pants in 2012) were included in the analyses (Fig. 1). The study 
protocol was approved by the institutional review board of the 
Korea University (KU-IRB-16-EX-272-A-1).
Basic characteristics
Sociodemographic data and lifestyle information were 
obtained using a health interview questionnaire, that included 
questions regarding sex, age, education level, smoking status, 
current drinking status, physical activity, and use of antihy-
pertensive medication. The education level was categorized as 
follows: completed elementary school, middle school, high 
school, or university education. The smoking status was classified 
into the following four groups: never-smoked, former smoker, 
smokes sometimes, and smokes every day. The drinking 
experience was classified as “no experience of drinking (no)” 
or “experience of drinking (yes).” To obtain information on 
physical activity, the participants were asked to report the time 
spent on walking, moderate activity, and vigorous activity. 
Physical activity was defined as participation in any of the 
following activities: walking for 30 min per day for at least 5 
days/week, moderate activity for 30 min per day for at least 
5 days/week, or vigorous activity for 20 min per day for at least 
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3 days/week. Use of antihypertensive medication was defined 
as taking antihypertensive medication at least once a month. 
Anthropometric information was obtained from the results of 
a health examination. Height and weight of the participants 
were measured by trained medical personnel as per standardized 
protocols. Body mass index (BMI) was calculated by dividing 
the weight in kilograms by the square of the height in meters 
(kg/m2). To measure biochemical markers, blood samples were 
collected after an 8-h fast. Serum triglyceride (TG; mg/dL), total 
cholesterol (TC; mg/dL), high-density lipoprotein cholesterol 
(HDL-C; mg/dL), fasting blood glucose (FBG; mg/dL), aspartate 
aminotransferase (AST; IU/L), and alanine aminotransferase (ALT; 
IU/L) levels were measured using enzymatic methods and a 
Hitachi automatic analyzer 7600 (Tokyo, Japan). Low-density 
lipoprotein cholesterol (LDL-C) levels were calculated according 
to the following equation: LDL-C (mg/dL) = TC (mg/dL) - HDL-C 
(mg/dL) - {[TG (mg/dL)/5] (TG < 400)} [24]. Glycosylated hemoglobin 
(HbA1c; %) was measured using high-performance liquid 
chromatography (HLC-723G7; Tosch, Tokyo, Japan).
Measurement of serum 25(OH)D levels
Blood samples were collected after an 8-h fast and immediately 
processed, refrigerated, and transported to the central testing 
institute (NeoDIN Medical Institute, Seoul, Korea). Serum 25(OH)D 
levels were measured within 24 h using radioimmunoassay (RIA) 
using a 1470 WIZARD gamma-counter (PerkinElmer, Turku, 
Finland) and a 25-Hydroxyvitamin D 125I RIA Kit (DiaSorin, MN, 
USA). In the present study, serum 25(OH)D levels were 
considered sufficient if they were ≥ 30 ng/mL, insufficient if 
they were between 20 ng/mL and 30 ng/mL, deficient if they 
were between 10 ng/mL and 20 ng/mL, and severely deficient 
if they were < 10 ng/mL [25]. Participants were divided into 
the following four groups based on their serum 25(OH)D levels: 
severe deficiency, deficiency, insufficiency, and sufficiency of 
serum 25(OH)D levels.
BP and hypertension
Measurement of BP was performed by a trained technician 
using a mercury sphygmomanometer (Baumanometer, NY, 
USA). The BP was measured three times on the right arm, and 
the average values of the second and third readings were 
recorded as the systolic BP (SBP) and diastolic BP (DBP) measure-
ments. Those with a self-reported history of physician-diagnosed 
HTN, BP >140/90 mmHg, or on antihypertensive medication 
were defined as having HTN.
Genetic variants
Five well-known serum 25(OH)D-related SNPs (DHCR7 rs1278 
5878; CYP2R1 rs10741657 and rs10741657; CYP24A1 rs6013897; 
and GC rs2282679) were selected from a previous GWAS [15] 
and MR studies [4,13,17-20,26]. DNA samples were extracted 
from the blood samples at the time of blood collection. Three 
vials of DNA samples (20 ug per vial) in ethylenediamine-
tetraacetic acid (EDTA) tube were stored in a deep freezer at 
-70°C. In 2017, about 6-7 years after the blood collection, we 
obtained 300 ng DNA samples from the National Biobank of 
Korea where the DNA samples were stored for genotyping [27]. 
Genotyping for rs12785878 (DHCR7), rs10741657 and rs12794714 
(CYP2R1), and rs6013897 (CYP24A1) was performed using a SNP 
type assay (Fluidigm, San Francisco, CA, USA), as per the 
manufacturer’s instructions at DNALINK, INC (Seoul, Korea). 
Genotyping of rs2282679 (GC) was further analyzed using the 
TaqMan assay method with a TaqMan fluorogenic 5′ nuclease 
assay (ABI, Foster City, CA, USA). Detailed methods of genotyping 
are described elsewhere [28,29]. 
Statistical analysis
All the statistical analyses were performed using Stata MP 13 
(Stata Corp LP, TX, USA). Data are reported as mean ± standard 
error values for the continuous variables and as number of 
counts and percentages for the categorical variables. Differences 
in the characteristics were evaluated using one-way analysis of 
variance (ANOVA) for continuous variables and chi-squared test 
for categorical variables. The effect allele frequency was calculated 
according to the following formula: (counts of heterozygotes
+ 2 × homozygotes of effect allele)/(2 × total counts). The 
strength of the associations between serum 25(OH)D levels and 
IVs was tested using the F-statistic. We conducted both 
observational and MR analyses to examine the relationships of 
serum 25(OH)D with HTN and BP values. The observational 
analysis for the associations between serum 25(OH)D levels and 
HTN/BP was conducted using the ordinary least squares (OLS) 
estimation method (in logistic regression models and linear 
regression models, respectively), adjusted for sex, age, BMI, 
education level, smoking status, drinking experience, physical 
activity, and use of antihypertensive medication as confounders. 
In the MR analysis, the effects of serum 25(OH)D levels on 
HTN/BP were estimated using an IV analysis with the two-stage 
least squares method. In the first stage, the association of 
individual genetic variants with serum 25(OH)D levels was 
tested in an additive model. The fitted serum 25(OH)D levels 
were then regressed on HTN/BP in the second stage. In the 
secondary analyses, we created a composite genetic risk score 
(GRS) (range 0-9) to assess the polygenic contribution of the 
loci associated with serum 25(OH)D by summing the number 
of 25(OH)D-increasing alleles across the five SNPs. Weighted 
GRS (wGRS) (range 0-9.5) was created by weighing each allele 
by its effect size reported in a previous GWAS [30]. We further 
created two separate function-based GRSs: synthesis score 
(range 0-6) using three SNPs relevant for synthesis of 25(OH)D 
(DHCR7 rs12785878, CYP2R1 rs10741657 and rs12794714;) and 
metabolic score (range 0-4) using two SNPs associated with 
transfer and clearance of 25(OH)D (CYP24A1 rs6013897, GC 
rs2282679). Results are presented as odds ratios (ORs) and 95% 
confidence intervals (CIs) for HTN and β coefficient and 95% 
CIs for BP.
RESULTS
General characteristics according to the serum 25(OH)D levels
Total 2,591 participants with both genetic and serum vitamin 
D data were included in our analyses. The basic characteristics 
of the study participants included are shown in Table 1. The 
prevalence of vitamin D sufficiency (serum 25(OH)D ≥ 30 ng/mL) 
was very low (n = 71; 2.7%). There were differences in the age, 
sex, BMI, education level, smoking status, and use of antihyper-
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Serum vitamin D categories (ng/mL)
Severe deficiency
(n = 190)
Deficiency
(n = 1,733)
Insufficiency
(n = 597)
Sufficiency
(n = 71) P-value†
[0-10] ng/mL [10-20] ng/mL [20-30] ng/mL [≥30] ng/mL
Serum 25(OH)D levels (ng/mL) 8.4 ± 0.1a 15.0 ± 0.1b 23.3 ± 0.1c 33.6 ± 0.5d < 0.001
Lifestyle variables
Age (yrs) 44.8 ± 1.1a 48.7 ± 0.4b 55.2 ± 0.6c 59.5 ± 1.6c < 0.001
Male (%, n) 26.8 (51) 45.9 (796) 59.1 (353) 52.1 (37) < 0.001
Body mass index (kg/m2) 23.0 ± 0.2a 24.1 ± 0.1b 24.1 ± 0.1b 23.9 ± 0.4ab < 0.001
Education (elementary school/middle school/high school/ 
university) (%)
12.6/13.1/36.6/37.7 20.3/11.1/37.0/31.7 32.0/15.7/30.2/22.1 35.2/18.3/31.0/15.5 < 0.001
Smoking status (never/former/sometimes/daily) (%) 69.2/11.5/0.6/18.7 57.2/19.9/2.2/20.7 45.9/29.4/1.0/23.7 49.3/23.9/4.2/22.5 < 0.001
Drinking experience (no/yes) (%) 9.9/90.1 10.8/89.2 12.6/87.4 18.3/81.7 0.150
Physical activity (%, n) 45.6 (83) 44.9 (764) 47.8 (277) 47.9 (34) 0.659
Use of antihypertensive medication (%, n) 19.7 (36) 19.1 (323) 26.5 (152) 31.0 (22) < 0.001
Cardiovascular risk factors
TG (mg/dL)* 131.9 ± 7.1 139.7 ± 3.0 136.6 ± 3.2 129.4 ± 10.1 0.336
TC (mg/dL) 183.1 ± 2.5 189.9 ± 0.9 190.8 ± 1.4 184.5 ± 4.6 0.036
HDL-C (mg/dL) 49.5 ± 0.9 49.7 ± 0.3 49.1 ± 0.5 48.2 ± 1.4 0.592
LDL-C (mg/dL) 108.2 ± 2.3 113.7 ± 0.8 114.5 ± 1.4 110.6 ± 4.2 0.094
FBG (mg/dL)* 95.4 ± 1.2a 99.0 ± 0.5ab 100.1 ± 0.8b 101.0 ± 2.2b 0.011
HbA1c (%)* 5.62 ± 0.05a 5.77 ± 0.02ab 5.85 ± 0.03ab 5.93 ± 0.09b 0.002
AST (IU/L)* 22.6 ± 2.2a 22.9 ± 0.4a 23.6 ± 0.4b 25.6 ± 1.3b < 0.001
ALT (IU/L)* 22.2 ± 4.1a 22.7 ± 0.5b 22.0 ± 0.6b 25.7 ± 2.5b < 0.001
Values are expressed as means ± standard errors for continuous variables and number of counts and percentages for categorical variables. 
† Statistical differences among the vitamin D groups were determined using one-way ANOVA with Bonferroni’s multiple comparison for continuous variables and chi-squared 
test for categorical variables. 
* Tested after log-transformation. 
TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBG, fasting blood glucose; Hb1Ac, glycosylated 
hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 1. Characteristics of the study participants as per the serum vitamin D level categories
tensive medication among the groups stratified as per the 
serum 25(OH)D levels. However, there were no differences in 
their drinking experience and physical activity levels. Analyses 
of the biochemical risk markers showed that TC, FBG, HbA1c, 
AST, and ALT levels were different among the serum 25(OH)D 
groups. However, these differences were attenuated after 
adjustment for sex and age (data not shown).
General characteristics as per the genotype of serum vitamin 
D-related SNPs
Genotypes are randomly assigned at conception; therefore, 
IVs are unlikely to be related to the potential confounders. To 
confirm the lack of association between the IVs and the 
potential confounders (one of the assumptions for IV), we 
compared the distributions of the participant characteristics by 
genotypes (Table 2). For each SNP, the potential confounders 
such as age, sex, BMI, education level, smoking status, drinking 
experience, physical activity, use of antihypertensive medication, 
and biochemical risk markers did not differ by genotypes.
Association between the vitamin D-related SNPs and serum 
25(OH)D levels
Table 3 summarizes the genetic information of the five 
vitamin D-related SNPs. Serum 25(OH)D-increasing alleles were 
termed effect alleles, and their frequencies are presented. For 
all five SNPs, 25(OH)D-increasing alleles were positively associated 
with serum 25(OH)D levels, as shown by β coefficients. Of these, 
the associations were strongest for rs2282679 (per allele: β =
0.639 ng/mL, F-statistics = 14.31, P < 0.001) and rs12785878 (per 
allele: β = 0.579 ng/mL, F-statistics = 13.34, P < 0.001). Other 
three SNPs (rs10741657, rs12794714, rs6013897) had F-statistics 
< 10, demonstrating the possibility of weak instrument bias.
Association of the serum 25(OH)D levels with HTN and elevated 
BP: Observational and MR estimates
The association between circulating 25(OH)D levels and HTN 
is presented in Table 4. In the observational analysis, serum 
25(OH)D levels were associated with a decreased prevalence 
of HTN (per 1 ng/mL increase: OR: 0.97, 95% CI: 0.94, 0.99) in 
the OLS models. SBP was inversely associated with serum 
25(OH)D levels (β: -0.13 mmHg, 95% CI: -0.24, -0.03); however, 
DBP did not show such an association. The MR analysis showed 
no strong pattern of association between the serum 25(OH)D 
levels and HTN using individual SNPs as IVs. Although the CIs 
were wide, genetically determined serum 25(OH)D levels 
tended to be inversely associated with SBP but not with DBP. 
For rs6013897 (CYP24A1), the association tended to be inverse 
with both HTN (OR: 0.76, 95% CI: 0.26, 2.25) and BP (β: -5.46 
mmHg, 95% CI: -23.7 to 12.8 for SBP; β: -2.08 mmHg, 95% CI: 
-10.1 to 5.93 for DBP). Similar results were observed for the 
GRSs (Supplementary Table 1 and 2).
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SNP Nearest gene Chr
Serum 25(OH)D
increasing allele
EAF F-statistic† β coefficient† P-value†
rs12785878 DHCR7 11 T 0.379 13.34 0.579 < 0.001
rs10741657 CYP2R1 11 A 0.398 3.97 0.315 0.046
rs12794714 CYP2R1 11 A 0.605 7.04 0.425 0.008
rs6013897 CYP24A1 20 A 0.113 0.48 0.170 0.488
rs2282679 GC 4 T 0.701 14.31 0.639 < 0.001
† F-statistic, β coefficient, and P-value were obtained from the first-stage regression of serum 25(OH)D levels on genotype. 
SNP, single nucleotide polymorphism; Chr, Chromosome; EAF, Effect allele frequency.
Table 3. Characteristics of single nucleotide polymorphisms used as an instrumental variable for serum 25(OH)D levels
Disease hypertension
Blood pressure
SBP (mmHg) DBP (mmHg)
OR (95% CI) P-value β coefficient (95% CI) P-value β coefficient (95% CI) P-value
OLS estimation†
Serum 25(OH)D (Per 1 ng/mL increase) 0.97 (0.94, 0.99) 0.01 -0.13 (-0.24, -0.03) 0.01 -0.06 (-0.13, 0.01) 0.13
IV estimation‡
rs12785878 (DHCR7; T allele) 1.05 (0.86, 1.29) 0.61 0.81 (-0.83, 2.45) 0.33 -0.47 (-1.52, 0.58) 0.38
rs10741657 (CYP2R1; A allele) 1.10 (0.76, 1.60) 0.61 -1.72 (-5.26, 1.82) 0.34 0.44 (-1.46, 2.34) 0.65
rs12794714 (CYP2R1; A allele) 1.03 (0.78, 1.36) 0.84 -1.24 (-3.72, 1.24) 0.33 0.55 (-0.90, 2.00) 0.46
rs6013897 (CYP24A1; A allele) 0.76 (0.26, 2.25) 0.62 -5.46 (-23.7, 12.8) 0.56 -2.08 (-10.1, 5.93) 0.61
rs2282679 (GC; T allele) 1.03 (0.84, 1.25) 0.78 -0.44 (-1.94, 1.24) 0.67 0.05 (-0.93, 1.03) 0.92
† Odds ratio (OR) and β coefficients were obtained from standard regressions using the OLS estimation method (in logistic regression models and linear regression models, 
respectively). Models were adjusted for sex, age, BMI, education level, smoking status, drinking experience, physical activity, and use of antihypertensive medication as 
confounders. 
‡ OR and β coefficients were obtained from IV regressions using two-stage least squares estimation method (in logistic regression models and in linear regression models, 
respectively), using individual genetic variants as instrument variables for serum 25(OH)D levels per serum 25(OH)D-increasing allele. 
SBP, systolic blood pressure; DBP, diastolic blood pressure; OLS, ordinary least square; OR, odds ratio; 95% CI, 95% confidence interval.
Table 4. Ordinary least square estimates and instrumental variable estimates for the relationships between serum 25(OH)D levels and hypertension outcomes
DISCUSSION
The main finding of this study was that there was no 
association between the serum 25(OH)D levels and HTN in 
Korean population in a framework of MR. However, our observa-
tional analyses from the same data showed that serum 25(OH)D 
levels were inversely associated with both HTN and SBP, 
consistent with the findings from other observational studies 
[1,28,29]. A cross-sectional analysis of the KNHANES 2009-2012 
data showed an inverse association between vitamin D levels 
and HTN in young and middle-aged Korean women (OR: 0.93, 
95% CI: 0.58, 0.91) [31]. In another study on middle-aged Korean 
adults, 3,234 participants with normal BP were followed up for 
4 years and those with serum vitamin D levels less than the 
median value had a higher risk of HTN (OR: 2.74, 95% CI: 1.40, 
5.34) [32]. Similarly, most studies in Western populations have 
reported an inverse association between the serum 25(OH)D 
levels and incident HTN [2,33]. However, results from these 
observational analyses are prone to bias because of confoun-
ding factors and reverse causation.
The lack of association between genetically determined serum 
25(OH)D and HTN observed in the present study is inconsistent 
with results from previous MR studies of European and North- 
American populations that report a favorable association 
between an increase in genetically instrumented 25(OH)D levels 
with HTN and BP values [13,14]. The difference in the associa-
tions may be explained by the biological differences in the 
ability of vitamin D synthesis and metabolism among different 
racial groups [34]. Awumey et al. [35] reported that Indians have 
altered vitamin D endocrine systems and lower serum 25(OH)D 
levels than Caucasians. The lack of association with HTN in 
our study can also be explained by the limited sample size and 
possible weak instrument bias. Our data showed that three 
of five SNPs (rs10741657, rs12794714, rs6013897) were only 
weakly associated with the serum 25(OH)D levels (F-statistics 
< 10); thus, these SNPs may have been weak instruments 
leading to underestimation of the associations with HTN. Using 
BP as an outcome, we found a general tendency for inverse 
associations between genetically determined vitamin D levels 
and SBP, possibly due to an increased power in the analyses 
using continuous variables. To overcome problems with weak 
instrument bias and increase the statistical power, we used GRSs 
(weighted GRS, synthesis score, and metabolism score) as IVs. 
The strength of the IV assessed using F-statistic was increased 
from 12.68 (metabolism score) to 27.18 (wGRS). However, the 
results of the GRSs analyses consistently disprove a causal role 
of vitamin D in BP.
Violation of the assumption of IVs (pleiotropy) can result in 
several biases [36]. Pleiotropy occurs when the genetic variant 
affects the outcome through biological pathways other than 
the targeted mechanism of interest. It has been reported that 
DHCR7 and CYP2R1 genes are valid for the assumption of 
exclusion restriction [21]. However, DHCR7 gene encodes enzyme- 
converting 7-dehydrocholesterol to cholesterol involved in 
cholesterol synthesis [21,37], thus the possibility of pleiotropy 
cannot be completely ruled out. However, DHCR7 was not 
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associated with the serum cholesterol level in our study (Table 
2; P-value = 0.328), and a previous large GWAS study of blood 
lipid [38] did not identify genome-wide significant association 
with DHCR7 gene. CYP2R1 gene encodes the vitamin D 
25-hydroxylase enzyme that converts vitamin D to 25(OH)D [39]. 
CYP2R1 is directly and biologically associated with the serum 
vitamin D levels; thus, it could be the best IV for MR studies 
on vitamin D [21]. Previous MR studies have demonstrated 
biological evidence of pleiotropy in two genes (CYP24A1 and 
GC) involved in the metabolism of vitamin D [13,21]. These 
genes reportedly control the free vitamin D levels through a 
feedback-loop [40]. By examining the association between 
genotypes and biomarkers, we tested whether pleiotropy would 
occur in our study. Based on the results shown in Table 2, there 
was no significant association between genotypes and biomarkers 
except for serum vitamin D levels. This can partially support 
that these genes influence the outcome only through serum 
vitamin D levels. We additionally conducted the MR-Egger test 
for pleiotropy [41]. The results showed no evidence of 
pleiotropy according to the intercept of MR-Egger (P = 0.74).
To our knowledge, this is the first study to examine the causal 
effects of serum 25(OH)D levels on HTN and BP in a Korean 
population using the MR approach. This study has several 
strengths. In the MR analyses, bias due to confounding factors 
and reverse causation is likely to be reduced. The concept of 
randomly allocated genotypes at conception (Mendel’s law of 
independent assortment) is similar to that in a randomized 
controlled trial, in which the exposure is randomly assigned to 
each group [42]. Within both frameworks, individuals are 
assigned to random groups with balanced distributions of 
factors that generally confound the relationship between serum 
vitamin D levels and HTN. In addition, MR is unaffected by 
reverse causation because of the clear temporal sequence 
between the genotype and the outcome. Our results showed 
that each IV was independent of the potential confounders that 
we evaluated, including age, sex, BMI, education level, smoking 
status, drinking experience, physical activity, and use of 
antihypertensive medication. Thus, our results are unlikely to 
be confounded by these factors, although we cannot eliminate 
the possibility of confounding even in MR analysis. Further, 
contrary to a single measurement of serum 25(OH)D level used 
in the observational analyses, genetically determined vitamin 
D level used in the MR analyses had a lower measurement error, 
was less likely to be influenced by season or region (e.g., 
latitude) in which the blood samples were collected, and was 
more likely to represent lifelong exposure levels of vitamin D. 
Despite these strengths, this study has certain limitations. 
Genetic variants used as IVs in our study were not selected from 
an East Asian GWAS because previous GWASs on serum 
25(OH)D levels were limited to European and South Asian 
populations [15,16,43,44]. However, a recent MR study on a 
Chinese population has demonstrated the associations of these 
SNPs with circulating vitamin D levels [17], supporting the use 
of these SNPs as IVs in East Asian subjects. In this study on 
a Korean population, we also confirmed that each SNP was 
associated with the serum 25(OH)D levels and the directions 
of association were consistent with previous studies [15,16].
In conclusion, this study does not support the causal effects 
of circulating 25(OH)D levels on HTN in Korean adults. The lack 
of association observed in the present MR study could be 
attributed to the relatively small sample size and possible weak 
instrument bias. However, to our knowledge, this is the only 
data set available for examining the associations among 
genotype, serum 25(OH)D levels, and HTN in the general Korean 
population. Our study contributes to the understanding of the 
association between serum 25(OH)D levels and prevalence of 
HTN, the prevalence of which has been continuously increasing 
in the Korean population. However, further MR studies with 
larger sample sizes are required for confirming the present 
results.
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